Cleared Traditional

K993108 - VARELISA RECOMBI ANA SCREEN EIA, MODELS 128 48/ 128 96

K993108 is an FDA 510(k) clearance for VARELISA RECOMBI ANA SCREEN EIA, manufactured by Pharmacia & Upjohn Co.. The device is a Class 2 Immunology device with product code LJM cleared through the Traditional 510(k) pathway after a 56-day FDA review.

K993108 · Pharmacia & Upjohn Co. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1999
Decision
56d
Days
Class 2
Risk

K993108 is an FDA 510(k) clearance for the VARELISA RECOMBI ANA SCREEN EIA, MODELS 128 48/ 128 96. Classified as Antinuclear Antibody (enzyme-labeled), Antigen, Controls (product code LJM), Class II - Special Controls.

Submitted by Pharmacia & Upjohn Co. (Westervillle, US). The FDA issued a Cleared decision on November 12, 1999 after a review of 56 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5100 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Pharmacia & Upjohn Co. devices

FDA 510(k) Submission Details - K993108

510(k) Number K993108 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 17, 1999
Decision Date November 12, 1999
Days to Decision 56 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
49d faster than avg
Panel avg: 105d · This submission: 56d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LJM Device Classification - Class 2, Special Controls

Product Code LJM Antinuclear Antibody (enzyme-labeled), Antigen, Controls
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - LJM Antinuclear Antibody (enzyme-labeled), Antigen, Controls

All 66
Devices cleared under the same product code (LJM) and FDA review panel - the closest regulatory comparables to K993108.
EL-ANA PROFILES-2K1
K002559 · Theratest Laboratories, Inc. · Sep 2000
THE APTUS (AUTOMATED) APPLICATION OF THE TG IGG ELISA TEST SYSTEM. AN ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) FOR THE
K000879 · Zeus Scientific, Inc. · May 2000
THE APTUS (AUTOMATED APPLICATION OF THE TPO IGG ELISA TEST SYSTEM. AN ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) FOR THE
K000880 · Zeus Scientific, Inc. · May 2000
VARELISA RECOMBI ANA PROFILE
K993109 · Pharmacia & Upjohn Co. · Nov 1999
RELISA ANA SCREENING TEST SYSTEM, MODEL 7096-11
K992041 · Immuno Concepts, Inc. · Jul 1999
AUTOSTAT II ANA SCREEN ELISA
K983655 · Cogent Diagnotics , Ltd. · Jan 1999